- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Success in Value-Based Contracting—Using Evidence, Technology, and Data to Improve Outcomes and Eliminate Low-Value Care, Part 4
Experts from Optum, WellMed, and Reliant discuss strategies for bringing value-based payment into specialty care through the use of education and analytics.
In the latest Matters in Managed Care webinar, experts discussed how to improve outcomes and eliminate low-value care. They defined actions and practices that constitute wasted and harmful care, described how to rapidly translate high-quality evidence-based medicine into daily practice, recognized how to leverage technology, and more.
Ken Cohen, MD, FACP, senior medical director and executive director, clinical research national senior medicaldirector, Optum Care, moderated the panel with:
- Troy Comstock, MD, regional medical director, Florida WellMed Medical Management
- Dan Murrey, MD, MPP, chief medical officer, surgical care associates; president, OptumCare Specialty Practices
- Thad Schilling, MD, chief medical officer, Reliant Medical Group
In segment 4, they discussed incorporating medication into the total cost of care.
Designing Care for the Underserved Creates Higher-Value Health Solutions
January 12th 2025In the second half of our interview with Brita Roy, MD, MPH, MHS, NYU Grossman School of Medicine, she discusses effective engagement of minoritized populations in discussion of medical mistrust.
Read More
Frameworks for Advancing Health Equity: Youth Behavioral Health Strategy Program
September 17th 2024Chris Barton, LCSW, of Horizon Blue Cross Blue Shield of New Jersey, explores how the Youth Behavioral Health Strategy program focuses on addressing the specific needs of youth with mental health and substance use issues through a comprehensive approach.
Listen
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials
January 9th 2025Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).
Read More
Decisions and Precision in Value-Based Cancer Care
January 7th 2025An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.
Read More
